MedTrace Logo

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

NCT01416688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 146

Last updated 2022-12-15

No results posted yet for this study

Summary

RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.

PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.

Conditions

Interventions

PROCEDURE

assessment of therapy complications

Will be given by questionnaire

PROCEDURE

psychosocial assessment and care

Will be given by questionnaire

PROCEDURE

quality-of-life assessment

Will be given by questionnaire

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Laurence H. Baker, DO, FACOI · University of Michigan Rogel Cancer Center

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-15
Primary Completion
2018-05-01
Completion
2019-04-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01416688 on ClinicalTrials.gov